Harvard Business Review

MARCH 2, 2011

Among my questions to them: How are you thinking about strategy these days? Some tentative conclusions: There is not much of a market for stand-alone strategy studies any more. Strategy has triumphed, the installed base is huge, no self-respecting company would be without one. This poses a dilemma for consulting firms.

Consultative 15

Consultative Strategy McKinsey Porter 15

Strategy Driven

JULY 13, 2011

Medium-term value drivers look forward to indicate whether a company can maintain and improve its revenue growth and ROIC over the next one to five years (or longer for companies, such as pharmaceutical manufacturers, that have long product cycles). Copyright (c) 2011. As with the other measures, what is important varies by industry.

ROIC 62

ROIC Balanced Scorecard Metrics McKinsey 62

Strategy Driven

MARCH 18, 2011

The Essential Advantage : How to Win with a Capabilities-Driven Strategy. The conventional wisdom about strategy may be leading your company astray. In this unpredictable economy, traditional approaches to strategy are a luxury most companies cannot afford. SD : What is ‘capabilities-driven strategy?’. Let’s go after it.”

Resources 52

Resources Industry System Strategy 52

Harvard Business Review

DECEMBER 20, 2011

The two biggest product stories of 2011 were arguably Lipitor and the iPhone 4S. The iPhone 4S's story seems to be about a new beginning: the highly anticipated launch of the latest version of a blockbuster consumer-technology product. Technology observers were initially underwhelmed by the iPhone 4S. Both Pfizer and.

Disintermediation 15

Disintermediation Industry Pharmaceuticals Price 15

Harvard Business Review

AUGUST 3, 2012

They might make a targeted acquisition here or there, form an alliance now and again, or license in some specialized technology, but by and large they made their own drugs, supporting big, fully staffed research labs, which they would then market themselves. Historically, big pharma firms made their own drugs.

Licensing 13

Licensing Depreciation Pharmaceuticals Budgeting 13

Harvard Business Review

JANUARY 26, 2011

Companies included in the ETF include major airlines, pharmaceuticals, industrials, and technology. agreed and added, "More and more of my clients are making sustainability a core part of their business strategy and they want to be able to report on this, with integrated reporting being the best way for them to do so.".

Long-term 15

Long-term Sample Report Pharmaceuticals 15

Harvard Business Review

DECEMBER 27, 2016

Healthcare has become extraordinarily complex — the balance of quality against cost, and of technology against humanity, are placing ever-increasing demands on clinicians. These challenges require extraordinary leaders. ” But this is changing. Might there be a general message here?

Management 15

Management 360-Degree Feedback Mayo Training 15